Drug-Drug Interaction Between PK101-001 and PK101-002

A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.

To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.

Inclusion Criteria:

• Healthy adults ≥ 19 years of age (on the day of screening)
• No congenital or chronic diseases and no abnormal signs determined by medical examinations
• Not abnormal or not clinical significant lab values
• 90mmHg ≤ (SBP) ≤ 139mmHg, 60mmHg ≤ (DBP) ≤ 89mmHg
• 18Kg/(m)^2 ≤ (BMI) ≤30Kg/(m)^2

Exclusion Criteria:

• Subjects who were administered below medications within 30 days (barbiturates, drugs of induced or suppressive drug metabolizing enzyme, etc)
• Subjects who were administered medications of prohibition within 10 days
• Heavy drinking within 30 days (female: over 14units/week, male:over 21units/week)
• Heavy smoker within 30 days (over 20 cigarettes per day)
• Subjects who previously participated in other clinical trials or bioequivalence Test within 90 days
• Subjects who donated whole blood within 60 days or donated component blood within 14 days or received blood transfusion within 30 days
• Subjects who have hypersensitivity for investigational products